Distribution of bluetongue and other arboviruses in northern Australia

A serological survey of cattle from throughout Queensland and sheep from cattle/sheep interface areas was conducted to determine the distribution and prevalence of antibodies to Bluetongue virus serotypes. This information allowed preliminary designation of arbovirus-free zones and identification of livestock populations at greatest risk to introduction of exotic Bluetongue viruses. Throughout the state antibodies were detected to only serotypes 1 and 21. In cattle, prevalence decreased with increasing distance from the coast ranging from 73 % in the far north to less than 1 % in the southwest. In sheep, prevalence of bluetongue antibodies in the major cattle/sheep interface areas in the north-west and central Queensland ranged from 0% to 5%. A system of strategically placed sentinel herds of 10 young serologically negative cattle was established across northern Australia to monitor the distribution and seasonality of bluetongue viruses. Initially 23 herds were located in Queensland, 4 in Northern Territory and 2 in Western Australia but by the completion of the project the number of herds in Queensland had been reduced to 12. No bluetongue virus activity was detected in Western Australia or Northern Territory herds throughout the project although testing of one herd in Northern Territory with a history of bluetongue activity was not done after June 1991. In Queensland, activity to bluetongue serotypes 1 and 21 was detected in all years of the project. Transmissions occurred predominantly in the period April to September and were more widespread in wetter years. The pathogenic bluetongue serotypes previously isolated from the Northern Territory have not spread to adjoining States

The Cooler Koozie, optimizing thermal insulation for beverage consumption

Our work aims to develop a new koozie with insulating properties that improve upon the current available commercial options. The hot climate of South Carolina, especially during football season, can heat a consumer\u27s beverage to an unenjoyable temperature in a very short period of time. To recreate these hot conditions in a lab setting, our team designed a hot air circulation box with a temperature controller. Our baseline for improvement was established by testing plain cola cans without koozies, cans with basic foam koozies, and cans with more expensive, name brand koozies. Based on these results, we set out to design a new koozie that would outperform those on the current market. Our design focuses on separating the can from the environment by maximizing captured air space between the two. Air is exploited in our design due to its low thermal conductivity, or ability to reduce heat transfer. The material of construction for our koozie is thin wall, flexible PVC tubing wound around in a spiral manner, and then glued together. We are also investigating different diameter tubing to determine the effect differing amounts air space. These results show that our new design has improved insulating properties compared to commercially available koozies while also being aesthetically pleasing

Synthetic, Structural and Computational Studies on Heavier Tetragen and Chalcogen Triazenide Complexes

The syntheses of the triazenide complexes [{N(N Dipp) 2} 2M] (Dipp = 2,6-di-isopropylphenyl; M = Ge(II) (1), Sn(II) (2), Pb(II) (3), and Te(II) (5)) are described for the first time. These compounds have been characterized by single-crystal X-ray diffraction and heteronuclear NMR spectroscopy. Density functional theory calculations were employed to confirm the presence and nature of the stereochemically active lone pairs in 1-5, alongside the Gibbs energy changes for their general synthesis, which enable the rationalization of observed reactivities. </p

Engaging the next generation in Appalachian studies: building community and expanding outreach through technology and diversity of programming

https://scholarworks.moreheadstate.edu/student_scholarship_posters/1089/thumbnail.jp

Association between purchase of over-the-counter medications and ovarian cancer diagnosis in the Cancer Loyalty Card Study (CLOCS): observational case-control study

BACKGROUND: Over-the-counter (OTC) medications are frequently used to self-care for nonspecific ovarian cancer symptoms prior to diagnosis. Monitoring such purchases may provide an opportunity for earlier diagnosis. OBJECTIVE: The aim of the Cancer Loyalty Card Study (CLOCS) was to investigate purchases of OTC pain and indigestion medications prior to ovarian cancer diagnosis in women with and without ovarian cancer in the United Kingdom using loyalty card data. METHODS: An observational case-control study was performed comparing purchases of OTC pain and indigestion medications prior to diagnosis in women with (n=153) and without (n=120) ovarian cancer using loyalty card data from two UK-based high street retailers. Monthly purchases of pain and indigestion medications for cases and controls were compared using the Fisher exact test, conditional logistic regression, and receiver operating characteristic (ROC) curve analysis. RESULTS: Pain and indigestion medication purchases were increased among cases 8 months before diagnosis, with maximum discrimination between cases and controls 8 months before diagnosis (Fisher exact odds ratio [OR] 2.9, 95% CI 2.1-4.1). An increase in indigestion medication purchases was detected up to 9 months before diagnosis (adjusted conditional logistic regression OR 1.38, 95% CI 1.04-1.83). The ROC analysis for indigestion medication purchases showed a maximum area under the curve (AUC) at 13 months before diagnosis (AUC=0.65, 95% CI 0.57-0.73), which further improved when stratified to late-stage ovarian cancer (AUC=0.68, 95% CI 0.59-0.78). CONCLUSIONS: There is a difference in purchases of pain and indigestion medications among women with and without ovarian cancer up to 8 months before diagnosis. Facilitating earlier presentation among those who self-care for symptoms using this novel data source could improve ovarian cancer patients' options for treatment and improve survival. TRIAL REGISTRATION: ClinicalTrials.gov NCT03994653; https://clinicaltrials.gov/ct2/show/NCT03994653